Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | SOD1 | P00441 | 1/20 | 0.39 |
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.38 |
| ▸ | TTBK2 | Q6IQ55 | 5/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162870 | 0.77 | TRPA1 (0.40) | TTBK1TTBK2TGFBR1TGFBR2MKNK1 | |
| SCHEMBL173973 | 0.76 | AURKA (0.59) | GSK3BAURKASRCNTRK1 | |
| SCHEMBL166205 | 0.74 | TRPA1 (0.38) | TTBK1TTBK2TGFBR1TGFBR2MKNK1 | |
| SCHEMBL174728 | 0.69 | MEN1 (0.39) | GSK3BAURKATTBK1TTBK2 | |
| SCHEMBL162207 | 0.66 | MEN1 (0.44) | GSK3BAURKATTBK1TTBK2 | |
| SCHEMBL27700384 | 0.65 | GSK3A (0.43) | GSK3BGSK3ASOD1NTRK1 | |
| SCHEMBL31669638 | 0.64 | MEN1 (0.50) | CHRNA7 | |
| SCHEMBL12082734 | 0.64 | CDC7 (0.46) | GSK3ASYK | |
| SCHEMBL6661474 | 0.63 | TRPA1 (0.52) | GSK3BAURKAGSK3ATTBK1TTBK2 | |
| SCHEMBL786696 | 0.58 | GSK3B (0.87) | GSK3BAURKASRCGSK3ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | GSK3B 353/4885AURKA 174/4885SRC 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.